Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 535

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease

Open access
Micha, Renata, Imamura, Fumiaki, Wyler von Ballmoos, Moritz, Solomon, Daniel H., Hernán, Miguel A., Ridker, Paul M., Mozaffarian, Dariush·2011·The American Journal of Cardiology

Abstract

Inflammation predicts risk of cardiovascular disease (CVD) events, but the relation of drugs that directly target inflammation with CVD risk is not established. Methotrexate is a disease-modifying anti-rheumatic drug broadly used for treatment of chronic inflammatory disorders. We performed a systematic review and meta-analysis of evidence for relationships of methotrexate with CVD occurrence. Cohorts, case-control studies or randomized trials were included if they reported an association between methotrexate and CVD risk. Inclusions/exclusions were independently adjudicated, and all data were extracted in duplicate. Pooled effects were calculated using inverse-variance-weighted meta-analysis. Of 694 identified publications, 10 observational studies, in which methotrexate was administered among patients with rheumatoid arthritis, psoriasis, or polyarthritis met inclusion criteria. Methotrexate was associated with 21% lower risk of total CVD (n=10 studies, 95% CI=0.73-0.87, p<0.001), and 18% lower risk of myocardial infarction (n=5, 95% CI=0.71-0.96, p=0.01), without evidence for statistical between-study heterogeneity (p=0.30, p=0.33, respectively). Among prespecified sources of heterogeneity explored, stronger associations were observed in studies that adjusted for underlying disease severity (RR=0.64, 95% CI=0.43-0.96, p<0.01), and for other concomitant medication (RR=0.73, 95% CI=0.63-0.84, p<0.001). Publication bias was potentially evident (funnel plot, Begg’s test, p=0.06); excluding studies with extreme risk estimates did not, however, alter results (RR=0.81, 95% CI=0.74-0.89). In conclusion, methotrexate use is associated with lower risk of CVD among patients with chronic inflammation. These findings suggest that a direct treatment of inflammation may reduce CVD risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.amjcard.2011.06.054

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 535

Metadata

Authors
Micha, R., Imamura, F., Wyler von Ballmoos, M., Solomon, D. H., Hernán, M. A., Ridker, P. M., & Mozaffarian, D.
Venue
The American Journal of Cardiology
Publisher
Elsevier BV
Published
2011-11
Volume
108
Issue
9
Pages
1362-1370
ISSN
0002-9149 (ISSN-L)
OpenAlex
W2155123856
Cited by
535
References
28
FWCI
5.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease. https://app.cochat.ai/papers/10.1016/j.amjcard.2011.06.054
The paper
Micha, R., Imamura, F., Wyler von Ballmoos, M., Solomon, D. H., Hernán, M. A., Ridker, P. M., & Mozaffarian, D. (2011). Systematic Review and Meta-Analysis of Methotrexate Use and Risk of Cardiovascular Disease. The American Journal of Cardiology. https://doi.org/10.1016/j.amjcard.2011.06.054

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.